linjc16/ctgov huggingface dataset:
Ultrasound and Paediatric Endotracheal Tube Size

Study Overview
=================
Brief Summary
-----------------
The aim of the present study was to evaluate the role of ultrasound in paediatric patients to compare the correct size of an uncuffed endotracheal tube (ETT) with the minimal transverse tracheal diameter (MTTD) measured by ultrasound and with tube size predicted by different age-related formulas. The investigators hypothesize that a prediction of pediatric ETT is possible with the ultrasonographic measurement of the MTTD.

Official Title
-----------------
Role of Ultrasound Compared to Age-related Formulas for Uncuffed Endotracheal Intubation in a Paediatric Population

Conditions
-----------------
Uncuffed Endotracheal Intubation

Intervention / Treatment
-----------------
* Procedure: Ultrasonography of the trachea


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: written informed consent children <= 5 years of age elective surgery requiring endotracheal intubation Exclusion Criteria: missing informed consent allergy to ultrasound gel

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Elective pediatric surgery<br> | Procedure: Ultrasonography of the trachea<br>* Ultrasonographic measurement of the minimal transverse tracheal diameter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasound, Minimal transverse tracheal diameter, Endotracheal tube size, Paediatric age-based formulas, Sonographic measurement of the trachea
The Role of Microbiota on the Development of Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Relationship between human microbiota and epidemiology of lung cancer

Detailed Description
-----------------
In this study,We aim to find some kinds of human microbiota , which were associated with development of non-small cell lung cancer.

Official Title
-----------------
The Role of Microbiota on the Development of Lung Cancer

Conditions
-----------------
NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III, NSCLC Stage IV, Healthy Subjects

Intervention / Treatment
-----------------
* Other: without intervention type


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: non-small cell lung cancer patients Exclusion Criteria: long-term workers in the polluted environment, Patients who had used antibiotics within 1 month before sampling,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NCSLC group<br>NSCLC patients,including stage I to stage IV. | Other: without intervention type<br>* Without intervention,this study is just an observational study.<br>|
| Healthy subjects<br>healthy subjects | Other: without intervention type<br>* Without intervention,this study is just an observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship Between Human Microbiota and Epidemiology of Lung Cancer | Find some human microbes that are associated with the development of lung cancer, we can detect these human microbiological content as a biomarker of lung cancer. | 1 year |
Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease

Study Overview
=================
Brief Summary
-----------------
Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. At the same time intratympanic dexamethasone will be used to rescue hearing

Detailed Description
-----------------
For Alleviation of Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. Measured with pre and post therapy vestibular severity index. At the same time intratympanic dexamethasone will be used to rescue hearing measured with speech reception threshold and speech discrimination threshold

Official Title
-----------------
Objective Vestibular Evaluation & Rehabilitation With Intratympanic Dexamethasone and Gentamicin in Meniere's Disease

Conditions
-----------------
Vestibular Disorder Preservation

Intervention / Treatment
-----------------
* Drug: Gentamicin
* Drug: Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients of unilateral Meniere's disease with severe vestibular symptoms Exclusion Criteria: Bilateral disease, operated cases

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Patients with unilateral Meniere's disease with intractable vertigo will be administered two doses of intratympanic gentamicin plus dexamethasone 1 week apart
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vestibular severity index improvement<br>Improvement in vestibular symptoms with intratympanic gentamicin | Drug: Gentamicin<br>* Intratympanic gentamicin and dexamethasone administered in two doses one week apart<br>* Other names: Intratympanic gentamicin;Drug: Dexamethasone<br>* Intratympanic gentamicin and dexamethasone administered in two doses one week apart<br>* Other names: Intratympanic dexamethasone;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vestibular Rehabilitation | Improvement in vestibular severity index | Three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dexamethasone, gentamicin
Quartet™ Bad Oeynhausen Trial

Study Overview
=================
Brief Summary
-----------------
Primary objective of this study is to evaluate whether the use of a quadripolar left ventricular (LV) electrode compared to a standard bipolar LV electrode leads to lower non-responder rates in patients undergoing cardiac resynchronization therapy (CRT)

Official Title
-----------------
Quartet™ Bad Oeynhausen Trial

Conditions
-----------------
Congestive Heart Failure, Cardiac Resynchronization Therapy

Intervention / Treatment
-----------------
* Device: Application of quadripolar / bipolar LV electrodes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for CRT-D implantation according to current guidelines Ischemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) Sinus rhythm NYHA II-IV Age ≥ 18 years Written informed consent to participate in the study Exclusion Criteria: Right bundle brunch block Valvular cardiomyopathy Patient receiving a non-transvenous LV electrode Known pregnancy Age < 18 years Life expectancy < 1 year Atrial fibrillation / atrial flutter at the time of enrolment Inability to provide informed consent Participation in another study with active therapeutic arm Regular follow-up in the study center within the first 6 months after implantation not guaranteed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Quadripolar LV electrode<br>Application of a quadripolar LV electrode | Device: Application of quadripolar / bipolar LV electrodes<br> <br> |
| Active Comparator: Bipolar LV electrode<br>Application of a bipolar LV electrode | Device: Application of quadripolar / bipolar LV electrodes<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in peak oxygen consumption |  | 6 months | 
| Reduction of New York Heart Association (NYHA) functional class |  | 6 months | 
| Survival |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac resynchronization therapy; heart failure, congestive
Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Study Overview
=================
Brief Summary
-----------------
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).

Detailed Description
-----------------
Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients' routine therapy is dictated by this protocol. No randomization will be performed. All serious and non-serious adverse events will be recorded in the study CRF database.

Official Title
-----------------
Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)

Conditions
-----------------
Phosphomannomutase 2 Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent/assent by the patient and/or their legally authorized representative Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests Willing and able to adhere to study requirements described in the protocol and consent/assent documents Exclusion Criteria: Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG) Currently using investigational drug Blood loss of >250 mL or donated blood within 56 days, or donated plasma within 7 days, of study screening
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| collect clinical and biological information in patients with CDG-PMM2 |  | up to 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PMM2-CDG, CDG-Ia
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

Study Overview
=================
Brief Summary
-----------------
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Detailed Description
-----------------
Methods:A Multiple-Center, Randomized, Double-Blind.

Official Title
-----------------
A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence

Conditions
-----------------
Methamphetamine Dependence

Intervention / Treatment
-----------------
* Drug: Aripiprazole
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence. Must sign a Information consent form. Required to provide detailed address and phone number Exclusion Criteria: Serious organic disease. Suicide ideation or hurt others. Taking antipsychotic within two weeks before. drug allergy to Risperidone or Aripiprazole. pregnancy and breastfeeding women.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aripiprazole<br>Aripiprazole arm,5mg/pill,10mg/day.last12weeks. | Drug: Aripiprazole<br>* Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks<br>* Other names: Aopai H20041507;|
| Placebo Comparator: Sugar pill<br>placebo arm,5mg/pill,10mg/day,last12weeks | Drug: placebo<br>* placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| abstinent time of Methamphetamine addict | methamphetamine-positive urine test results,self-reports of substance use | up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of Participants with Adverse Events as a Measure of Safety and Tolerability | use Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale | up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Methamphetamine-Associated Psychosis, Aripiprazole
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This is a research study comparing the safety and efficacy of two active study medications

Official Title
-----------------
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression

Conditions
-----------------
Depression, Schizophrenia, Schizoaffective Disorder

Intervention / Treatment
-----------------
* Drug: olanzapine
* Drug: ziprasidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subjects 18-60 years of age Female subjects of childbearing potential must be using a medically accepted means of contraception Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol Subjects must be considered reliable Exclusion Criteria: Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry Female subjects who are either pregnant or nursing Uncorrected hypothyroidism or hyperthyroidism Narrow-angle glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: olanzapine|nan|
|Drug: ziprasidone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, Comorbid Depression, Schizophrenia, Schizoaffective Disorder
Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to quantify the excess mortality associated with non-adherence to care for non ST-elevation myocardial infarction in England and Wales over the last decade.

Official Title
-----------------
Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study

Conditions
-----------------
Non ST-elevation Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18 years or more patients hospitalised with non ST-elevation myocardial infarction Exclusion Criteria: patients hospitalised with phenotypes other than non ST-elevation myocardial infarction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | Participants will be followed up for an expected average of 8 years 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of missed guideline recommended care opportunities |  | Participants will be followed up for an expected average of 8 years 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MINAP, NSTEMI, excess mortality, evidence-based care
Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the use of combined fluid attenuated inversion recovery (FLAIR) imaging and diffusion weighted imaging (DWI) as surrogate marker of lesion age within the first 6 hours of ischemic stroke in order to identify patients ≤ 3 or ≤ 4.5 hours of symptom onset in a large multicenter study hours of ischemic stroke. The investigators hypothesize that the pattern of a visible lesion on DWI together with a negative FLAIR (DWI-FLAIR mismatch) will identify patients ≤ 3 hours of symptom onset with >80% specificity and positive predictive value.

Official Title
-----------------
PREdictive Value of FLAIR and DWI for the Identification of Acute Ischemic Stroke Patients ≤ 3 and ≤ 4.5 h of Symptom Onset - a Multicenter Observational Study

Conditions
-----------------
Acute Ischemic Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute ischemic stroke (proven by initial or follow-up MRI) Well defined and known symptom onset Stroke MRI including diffusion weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) sequences performed within 12 hours of symptom onset Informed consent Exclusion Criteria: Contraindications against MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute ischemic stroke<br>Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specificity (and 95% CI) of DWI-FLAIR-mismatch for the identification of patients ≤3 and ≤4.5 hours |  | on admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictors of a negative FLAIR in acute ischemic stroke |  | on admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ischemic stroke, thrombolysis, magnetic resonance imaging, diffusion weighted imaging, fluid attenuated inversion recovery, time window
Effect of Platelet Concentrate in Treatment of Diabetic Ulcers

Study Overview
=================
Brief Summary
-----------------
Autologous platelet concentrate will enhance the rate of healing of chronic diabetic wounds

Detailed Description
-----------------
The treatment of a diabetic wound with APC and thrombinhas the potential to accelerate the re-epithial process when compared with usual care. The study is a prospective, randomized, blinded, multicenter clinical evaluation.

Official Title
-----------------
Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic Ulcers

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Device: debridement, dressing, and APC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:chronic diabetic ulcer - Exclusion Criteria:steroids, dialysis, vascular disease -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: APC Treatment<br>wound debridement and treatment with APC | Device: debridement, dressing, and APC<br>* ebridement, dressing, and APC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, Ulcer, APC